Day One Biopharmaceuticals logo
Day One Biopharmaceuticals, Inc. (DAWN)
Apr 21, 2026 - DAWN was delisted (reason: acquired by Servier)
21.53
+0.04 (0.19%)
Inactive · Last trade price on Apr 22, 2026

DAWN Stock Forecast

Stock Price Forecast

The 8 analysts with 12-month price forecasts for DAWN stock had an average target of $24.43, with a low estimate of $21.5 and a high estimate of $34.

Price Target: $24.43 (+13.47%)
Analyst Consensus: Buy

Price Target

TargetLowAverageMedianHigh
Price$21.5$24.43n/a$34
Change-0.14%+13.47%n/a+57.92%

Analyst Ratings

The average analyst rating for DAWN stock from 8 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.

Recommendation Trends

No data available
RatingOct 2026
Strong Buyn/a
Buyn/a
Holdn/a
Selln/a
Strong Selln/a
Totaln/a

Financial Forecast

Revenue This Year
245.23M
from 158.18M
Increased by 55.03%
Revenue Next Year
314.20M
from 245.23M
Increased by 28.12%
EPS This Year
-0.89
from -1.04
EPS Next Year
-0.20
from -0.89
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
---131.16M158.18M245.23M314.20M
Revenue Growth
----20.60%55.03%28.12%
EPS
-4.62-2.17-2.37-1.02-1.04-0.89-0.20
No. Analysts
-----1110

Revenue Forecast

Revenue20262027202820292030203120322033
High265.0M362.8M
Avg245.2M314.2M
Low222.8M272.3M

Revenue Growth

Revenue Growth20262027202820292030203120322033
High
67.5%
47.9%
Avg
55.0%
28.1%
Low
40.8%
11.0%

EPS Forecast

EPS20262027202820292030203120322033
High-0.430.37
Avg-0.89-0.20
Low-1.98-0.62

EPS Growth

EPS Growth20262027202820292030203120322033
High--
Avg--
Low--